From old competence destruction to new competence access: Evidence from the comparison of two discontinuities in anticancer drug discovery

Organization Science

Volumn 22, Issue 6, 2011, Pages 1500-1516

  Sosa, M Lourdes ^a  

^a LONDON BUSINESS SCHOOL   (United Kingdom)

Author keywords

Biotechnology; Capabilities; Competence destroying; Incumbents; R D; Strategic renewal; Technological discontinuity

Indexed keywords

EID: 82455181918     PISSN: 10477039     EISSN: 15265455     Source Type: Journal    
DOI: 10.1287/orsc.1100.0616     Document Type: Article

References (60)

1. Agarwal, R., C. E. Helfat. 2009. Strategic renewal of organizations. Organ. Sci. 20(2) 281-293.
2. Ahuja, G., R. Katila. 2004. Where do resources come from? The role of idiosyncratic situations. Strategic Management J. 25(8-9) 887-907.
3. American Cancer Society. 2000. Cancer facts and figures 2000. Retrieved March 10, 2008, http://ww2.cancer.org/downloads/STT/F&F00.pdf.
4. American Cancer Society. 2004. Cancer facts and figures 2004. Retrieved March 25, 2009, http://ww2.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf.
5. Amit, R., P. J. H. Schoemaker. 1993. Strategic assets and organizational rent. Strategic Management J. 14(1) 33-46.
6. Barney, J. B. 1986. Strategic factor markets-Expectations, luck, and business strategy. Management Sci. 32(10) 1231-1241.
7. Barney, J. B. 1991. Firm resources and sustained competitive advantage. J. Management 17(1) 99-120.
8. Bazell, R. 1998. Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer. Random House, New York.
9. Capdeville, R., E. Buchdunger, J. Zimmermann, A. Matter. 2002. Glivec (STI571, Imanitib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discovery 1 493-502.
10. Cattani, G. 2005. Preadaptation, firm heterogeneity, and technological performance: A study on the evolution of fiber optics, 1970-1995. Organ. Sci. 16(6) 563-580.
11. Chabner, B. A., T. G. Roberts Jr. 2005. Chemotherapy and the war on cancer. Nature Rev. Cancer 5 65-72.
12. Chemical and Engineering News. 2005. List of top pharmaceuticals. 83(25, Special issue), http://pubs.acs.org/cen/coverstory/83/8325/8325list.html.
13. Christensen, C. M. 1997. The Innovator's Dilemma: The Revoluationary Book that Will Change the Way You Do Business. Harvard Business School Press, Boston.
14. Colwell, R. R. 2002. Fulfilling the promise of biotechnology. Biotechnology Adv. 20(3-4) 215-228.
15. Dierickx, I., K. Cool. 1989. Asset stock accumulation and sustainability of competition advantage. Management Sci. 35(12) 1504-1511.
16. Drews, J. 1993. Into the 21st century: Biotechnology and the pharmaceutical industry in the next ten years. Biotechnology 11(3) S16-S20.
17. Eggers, J. P., S. Kaplan. 2009. Cognition and renewal: Comparing CEO and organizational effects on incumbent adaptation to technical change. Organ. Sci. 20(2) 461-477.
18. Ethiraj, S. K., P. Kale, M. S. Krishnan, J. V. Singh. 2005. Where do capabilities come from and how do they matter? A study in the software services industry. Strategic Management J. 26(1) 25-45.
19. Feldman, M. 2003. The locational dynamics of the US biotech industry: Knowledge externalities and the anchor hypothesis. Indust. Innovation 10(3) 311-329.
20. Ferrera, N., K. J. Hillan, H.-P. Gerber, W. Novotny. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discovery 3 391-400.
21. Gatignon, H., M. L. Tushman, W. Smith, P. Anderson. 2002. A structural approach to assessing innovation: Construct development of innovation locus, type, and characteristics. Management Sci. 48(9) 1103-1122.
22. Gibbons, A. 1991. Biotech pipeline: Bottleneck ahead. Science 254(5030) 369-370.
23. Groysberg, B., L.-E. Lee, A. Nanda. 2008. Can they take it with them? The portability of star knowledge workers' performance. Management Sci. 54(7) 1213-1230.
24. Hammond, E., M. Johnson. 2009. Credit Suisse leads bank sector higher. Financial Times (July 23) http://www.ft.com/cms/s/o/ab0757d0-7773-11de-8c68-00144fea.
25. Hannan, M. T., J. Freeman. 1984. Structural inertia and organizational change. Amer. Sociol. Rev. 49(2) 149-164.
26. Helfat, C. E., M. B. Lieberman. 2002. The birth of capabilities: Market entry and the importance of pre-history. Indust. Corporate Change 11(4) 725-760.
27. Kaplan, S., F. Murray. 2008. Entrepreneurship and the construction of value in biotechnology. N. Phillips, G. Sewell, D. Griffiths, eds. Technology and Organization: Essays in Honour of Joan Woodward. Research in the Sociology of Organizations, Vol. 29. Emerald Publishing, Bingley, UK, 107-147.
28. Lacetera, N., I. M. Cockburn, R. Henderson. 2004. Do firms change capabilities by hiring new people? A study of the adoption of science-based drug discovery. J. A. C. Baum, A. M. McGahan, eds. Business Strategy over the Industry Life Cycle. Advances in Strategic Management, Vol. 21. Emerald Publishing, Bingley, UK, 133-159.
29. Leader, B., Q. J. Baca, D. E. Golan. 2008. Protein therapeutics: A summary and pharmacological classification. Nature Rev. Drug Discovery 7 21-39.
30. Lieberman, M. B., D. B. Montgomery. 1988. First-mover advantages. Strategic Management J. 9(S1) 41-58.
31. Lu, Z. J., W. S. Comanor. 1998. Strategic pricing of new pharmaceuticals. Rev. Econom. Statistics 80(1) 108-118.
32. Marx, M. T. 2009. Essays on employee noncompete agreements. Unpublished doctoral dissertation, Harvard Business School, Boston.
33. Mitchell, W. 1991. Dual clocks: Entry order influences on incumbent and newcomer market share and survival when specialized assets retain their value. Strategic Management J. 12(2) 85-100.
34. Montgomery, C. A., B. Wernerfelt. 1988. Diversification, Ricardian rents, and Tobin's Q. RAND J. Econom. 19(4) 623-632.
35. Morton, L. T., R. J. Moore. 1997. A Chronology of Medicine and Related Sciences. Scolar Press, Hants, UK.
36. Mowery, D. C., N. Rosenberg. 1998. Paths of Innovation: Technological Change in 20th-Century America. Cambridge University Press, Cambridge, UK.
37. Nature. 2006. Nature milestones: Cancer. Retrieved April 24, 2009, http://www.nature.com/milestones/milecancer/timeline.html.
38. Nature. 2007. Nature milestones: DNA technologies. Retrieved April 24, 2009, http://www.nature.com/milestones/miledna/timeline.html.
39. Pearson, A. E., J. M. Hurstak. 1992. Johnson & Johnson in the 1990s. HBS Case 9-393-001, Harvard Business School, Boston.
40. Penrose, E. 1959. The Theory of the Growth of the Firm. Oxford University Press, Oxford, UK.
41. Puranam, P., H. Singh, S. Chaudhuri. 2009. Integrating acquired capabilities: When structural integration is (un)necessary. Organ. Sci. 20(2) 313-328.
42. Rang, H. P. 2006. The drug discovery process: general principles and some case histories. H. P. Rang, ed. Drug Discovery and Development: Technology in Transition. Churchill Livingstone, Philadelphia, 43-56.
43. Rothaermel, F. T. 2001. Incumbent's advantage through exploiting complementary assets via interfirm cooperation. Strategic Management J. 22(6-7) 687-699.
44. Rumelt, R. P. 1987. Theory, strategy, and entrepreneurship. D. J. Teece, ed. The Competitive Challenge: Strategies for Industrial Innovation and Renewal. Ballinger, Cambridge, MA, 137-158.
45. Simonian, H., A. Jack. 2005. Novartis wins Chiron after sweetening its offer. Financial Times (October 31), http://www.ft.com/cms/s/0/b9c4db34-49fb-11da-b8b1-0000779e2340.html#axzz1C5uVW1dy.
46. Simonian, H., A. Jack. 2009. Roche completes Genentech deal. Financial Times (March 27), http://www.ft.com/cms/s/0/323d1670-1a6f-11de-9f91-0000779fd2ac.html.
47. Sørensen, J. B., T. E. Stuart. 2000. Aging, obsolescence and innovation. Admin. Sci. Quart. 45(1) 81-112.
48. Sosa, M. L. 2009a. Application-specific R&D capabilities and the advantage of incumbents: Evidence from the anticancer drug market. Management Sci. 55(8) 1409-1422.
49. Sosa, M. L. 2009b. High-risk radical innovation and the role of de novo firms in the dynamics of creative destruction: Evidence from gene therapy research. Presentation, EGOS Conference 2009, July 2, European Group for Organizational Studies, Barcelona.
50. Sutton, J. 1998. Technology and Market Structure: Theory and Structure. MIT Press, Cambridge, MA.
51. Teece, D. J. 1986. Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy. Res. Policy 15(6) 285-305.
52. Tilton, J. E. 1971. International Diffusion of Technology: The Case of Semiconductors. Brookings Institution, Washington, DC.
53. Tripsas, M. 1997. Unraveling the process of creative destruction: Complementary assets and incumbent survival in the typesetter industry. Strategic Management J. 18(S1) 119-142.
54. Tushman, M., P. Anderson. 1986. Technological discontinuities and organizational environments. Admin. Sci. Quart. 31(3) 439-465.
55. Tyle, P., B. P. Ram. 1990. Monoclonal antibodies, immunoconjugates and liposomes as targeted therapeutic systems. P. Tyle, B. P. Ram, eds. Targeted Therapeutic Systems. Marcel Dekker, New York, 3-23.
56. Vasella, D., R. Slater. 2003. Magic Cancer Bullet: How a Tiny Orange Pill Is Rewriting Medical History. HarperCollins, New York.
57. Walsh, G. 2003. Biopharmaceuticals: Biochemistry and Biotechnology, 2nd ed. John Wiley & Sons, Chichester, UK.
58. Weber, J. 1992. A big company that works: J&J's Ralph Larsen gives his units a lot of latitude-And they produce. Bus. Week 3264(4) 124-127.
59. Wernerfelt, B. 1984. A resource-based view of the firm. Strategic Management J. 5(2) 171-180.
60. Williams, C., W. Mitchell. 2004. Focusing firm evolution: The impact of information infrastructure on market entry by U.S. telecommunications companies, 1984-1998. Management Sci. 50(11) 1561-1575.